Brokers Offer Predictions for Fibrocell Science Inc’s Q1 2018 Earnings (FCSC)
Fibrocell Science Inc (NASDAQ:FCSC) – Research analysts at Griffin Securities issued their Q1 2018 earnings estimates for shares of Fibrocell Science in a note issued to investors on Thursday. Griffin Securities analyst K. Markey expects that the company will post earnings per share of ($0.26) for the quarter. Griffin Securities also issued estimates for Fibrocell Science’s Q2 2018 earnings at ($0.29) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.23) EPS and FY2021 earnings at $1.05 EPS.
Fibrocell Science (NASDAQ:FCSC) last announced its earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). Fibrocell Science had a negative net margin of 4,307.60% and a negative return on equity of 293.07%.
A number of other brokerages have also recently weighed in on FCSC. Zacks Investment Research cut shares of Fibrocell Science from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. ValuEngine raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th. Finally, HC Wainwright set a $6.00 price target on shares of Fibrocell Science and gave the company a “buy” rating in a research report on Wednesday, August 9th.
Shares of Fibrocell Science (NASDAQ FCSC) opened at 2.68 on Monday. The stock’s market capitalization is $39.38 million. The company’s 50-day moving average is $3.61 and its 200 day moving average is $2.24. Fibrocell Science has a 52 week low of $1.57 and a 52 week high of $4.64.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC boosted its position in Fibrocell Science by 264.0% in the second quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock worth $194,000 after buying an additional 35,000 shares during the last quarter. Creative Planning boosted its position in Fibrocell Science by 395.3% in the second quarter. Creative Planning now owns 61,090 shares of the company’s stock worth $245,000 after buying an additional 48,755 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Fibrocell Science by 272.4% in the fourth quarter. Renaissance Technologies LLC now owns 194,000 shares of the company’s stock worth $122,000 after buying an additional 141,900 shares during the last quarter. 55.31% of the stock is currently owned by hedge funds and other institutional investors.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.